Hao Peng

Hao Peng

Auto-generated profile, based on publicly available information

Hao Peng

Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2024 in Drug Design, Development and Therapy
Verified
Journal Article
Open access
PDF file
MLMingyi Li
Mingyi Li
MJMeng Jin
Meng Jin
HPHao Peng
Hao Peng
HWHaitao Wang
Haitao Wang
QSQian Shen
Qian Shen
LZLei Zhang
Lei Zhang
Lung cancer is the leading cause of mortality worldwide, and non-small cell lung cancer accounts for the majority of lung cancer cases. Chemotherapy and radiotherapy constitute the mainstays of lung cancer treatment; however, their associated side effects involving the kidneys, nervous system, gastrointestinal tract, and liver further add to dismal outcomes. The advent of antibody‒drug conjugates (ADCs) could change this situation. Trophoblast surface antigen 2 (TROP-2), a human trophoblast surface antigen, is a tumor-associated antigen that is expressed at low levels in normal tissues and is overexpressed in a variety of malignant tumors. The differential expression of the TROP-2 protein in a variety of tumors makes tumor immunotherapy with ADCs targeting TROP-2 a promising approach. Previous studies have shown that the expression of TROP-2 is related to the prognosis of patients with lung cancer and that TROP-2 expression is different across different histological types; however, research on TROP-2 and TROP-2 ADCs in patients with lung cancer is not comprehensive. The aims of this study were to review the mechanism of action and clinical efficacy of TROP-2 and related drugs in the treatment of lung cancer, to elucidate the prognostic value of TROP-2 in lung cancer, and to discuss the future prospects of TROP-2 ADCs to provide a reference for the precise treatment of lung cancer.

1 January 2024 in The World Journal of Men's Health
Verified
Journal Article
Open access
PDF file
HPHao Peng
Hao Peng
HZHanlin Zhang
Hanlin Zhang
SXSheng Xin
Sheng Xin
HLHao Li
Hao Li
XLXiaming Liu
Xiaming Liu
WSWen Song
Wen Song
Peng H, et al. World J Mens Health. 2024 Jan;42:e18. https://doi.org/10.5534/wjmh.230192

4 August 2025 in Cancer Research
Verified
Journal Article
Open access
SMSheng Ma
Sheng Ma
YGYue Ge
Yue Ge
ZLZequn Lu
Zequn Lu
JZJunbiao Zhang
Junbiao Zhang
QZQin Zhang
Qin Zhang
ZWZhihua Wang
Zhihua Wang
Prostate cancer is the most prevalent cancer among men worldwide and exhibits significant genetic heritability. In this study, we performed an integrative analysis combining chromatin accessibility profiling, transcriptomics, and two-stage case–control studies, alongside an unbiased phenome-wide exploration in the FinnGen cohort. This comprehensive approach identified the enhancer-associated SNP rs7077830 at chromosome 10q11 as a critical modulator of prostate cancer susceptibility. Mechanistic investigations revealed that rs7077830 exerted allele-specific enhancer activity, driving NCOA4 expression via a ZNF384-mediated enhancer–promoter interaction. CRISPR/Cas9-mediated single-nucleotide editing confirmed the direct regulatory role of rs7077830 on NCOA4 and its contribution to prostate cancer progression. Functional studies demonstrated that NCOA4 acted as a tumor suppressor by promoting ferroptosis. Furthermore, NCOA4 expression modulated sensitivity to ferroptosis-inducing agents. Strikingly, rs7077830 genotypes were directly linked to ferroptosis status in prostate cancer. These findings highlight the role of noncoding genetic variants in prostate cancer pathogenesis, provide insights into enhancer-driven ferroptosis regulation, and suggest a promising therapeutic avenue for patients with prostate cancer carrying specific rs7077830 genotypes. Significance: An enhancer mechanism mediated by a noncoding variant drives prostate cancer risk by regulating tumor suppressor expression and ferroptosis while conferring susceptibility to the potential of genotype-based precision therapeutic approaches.

1 October 2025
Verified
Other
Open access
SMSheng Ma
Sheng Ma
YGYue Ge
Yue Ge
ZLZequn Lu
Zequn Lu
JZJunbiao Zhang
Junbiao Zhang
QZQin Zhang
Qin Zhang
ZWZhihua Wang
Zhihua Wang
NCOA4 affects prostate cancer sensitivity to ferroptosis-inducing drug in vitro


1 October 2025
Verified
Other
Open access
SMSheng Ma
Sheng Ma
YGYue Ge
Yue Ge
ZLZequn Lu
Zequn Lu
JZJunbiao Zhang
Junbiao Zhang
QZQin Zhang
Qin Zhang
ZWZhihua Wang
Zhihua Wang
Genes affected by DARs play crucial roles in prostate cancer development